Drug Profile
Ganetespib - Aldeyra Therapeutics
Alternative Names: ADX 1612; SARC 023; STA-9090Latest Information Update: 29 Sep 2023
Price :
$50
*
At a glance
- Originator Synta Pharmaceuticals
- Developer Aldeyra Therapeutics; Cancer Research UK; Cardiff University; Emory University; Innsbruck Medical University; Madrigal Pharmaceuticals; Memorial Sloan-Kettering Cancer Center; Multiple Myeloma Research Consortium; Synta Pharmaceuticals
- Class Antineoplastics; Antivirals; Eye disorder therapies; Indoles; Resorcinols; Small molecules; Triazoles
- Mechanism of Action HSP90 heat-shock protein inhibitors; Nucleic acid inhibitors; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Acute myeloid leukaemia; Myelodysplastic syndromes
- Phase II Malignant-mesothelioma; Ovarian cancer
- Suspended Lymphoproliferative disorders
- Discontinued Breast cancer; Chronic myeloid leukaemia; Colorectal cancer; COVID 2019 infections; Fallopian tube cancer; Gastric cancer; Gastrointestinal stromal tumours; Head and neck cancer; Liver cancer; Malignant melanoma; Multiple myeloma; Neuroendocrine tumours; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Peritoneal cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer; Rectal cancer; Sarcoma; Small cell lung cancer; Uveal melanoma
Most Recent Events
- 01 Sep 2023 Katholieke Universiteit Leuven completes the phase II trial for Ovarian cancer (Combination therapy, Second line therapy or greater) in Belgium, France, Italy, Germany, Austria (NCT03783949)
- 29 Sep 2022 Discontinued - Phase-II for COVID-2019 infections (IV)
- 29 Sep 2022 Discontinued - Phase-II for Ovarian cancer (Combination therapy, Second-line therapy or greater) in Italy (IV)